北京福元医药股份有限公司投资者关系活 动记录表 编号：2024-22 | --- | --- | --- | |-------------------|-------------------------|----------------------------------------------------------------------| | | □ 特定对象调研 | £ 分析师会议 | | 投 资 者 关 系 活 | □ 媒体采访 √业绩说明会 | | | 动类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | | □其他（请文字说明其他活动内容） | | 参 与 单 位 名 称 | 线上参与公司 2024 | 年第三季度业绩说明会的全体投资者 | | 及人员姓名 | | | | 时间 | 10： 00-11：00 | | | 地点 | 上证路演中心 | https://roadshow.sseinfo.com | | | 董事长、总经理 黄河先生 | | | 上 市 公 司 接 待 | 财务负责人 杨徐燕女士 | | | 人员姓名 | 董事会秘书 李永先生 | | | ...

北京福元医药股份有限公司投资者关系活 动记录表 编号：2024-21 | --- | --- | --- | |------------------|-------------------------------|-----------------------------------------| | | √特定对象调研 £分析师会议 | | | 投资者关系活动类 | □媒体采访 £业绩说明会 | | | 别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | | | 中信证券 邵籽杰 宁波银行北京分行 孔晓朵 | | | | 英科资本 张洋洋 含章资本 李贵林 | | 参与单位名称及人 | 开熙投资 杨雪松 东兴证券 东芳 | | | 员姓名 | | 长江证券 夏锦 华福证券 萨日娜 | | | 北京海归协会 高连奎 | | | | 天津金融资产交易所 常韬玉 | | | 时间 | 15:00-16:00 | | | 地点 | 公司会议室 | | | | 董事会秘书 李永 | | | 上市公司接待人员 | 证券事务代表 郑凯微 | | ...

北京福元医药股份有限公司投资者关系活 动记录表 编号：2024-20 | --- | --- | --- | |-------------------------|---------------------------|--------------------------------------------------------| | | √特定对象调研 £分析师会议 | | | 投资者关系活动类 | □媒体采访 £业绩说明会 | | | 别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称及人 员姓名 | 华福医药 吴沛柯 | | | 时间 | 13：30-14 ： 30 | | | 地点 | 公司会议室 | | | | 董事会秘书 李永 | | | 上市公司接待人员 | 证券事务代表 郑凯微 | | | 姓名 | 董秘助理 姜钰 | | | 投资者关系活动主 | 1. 公司 2024 | 年前三季度核心产品收入情况，大致规模拆分 | | 要内容介绍 | | 回答：公司持续打造三体一位核心竞争优势，坚持多品种研发 | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase of over 15% compared to the CSI 300 index in the next six months [8][9]. Core Insights - The company reported a revenue of 2.547 billion yuan for the first three quarters of 2024, representing a year-over-year increase of 3.42%. The net profit attributable to shareholders was 401 million yuan, up 5.59% year-over-year [2]. - In Q3 2024, the company achieved a revenue of 892 million yuan, reflecting a year-over-year growth of 7.02% and a quarter-over-quarter increase of 4.57%. However, the net profit for Q3 decreased by 14.74% year-over-year [2]. - The company continues to invest heavily in research and development, with a R&D expense ratio of 12.13% in Q3 2024, an increase of 2.05 percentage points year-over-year [2]. Financial Performance Summary - The company’s projected revenues for 2024, 2025, and 2026 are 3.501 billion yuan, 3.780 billion yuan, and 4.083 billion yuan, respectively, with year-over-year growth rates of 4.83%, 7.96%, and 8.03% [3][4]. - The net profit attributable to shareholders is forecasted to be 519 million yuan, 593 million yuan, and 659 million yuan for the years 2024, 2025, and 2026, with growth rates of 6.26%, 14.12%, and 11.25% respectively [3][4]. - The company’s gross margin in Q3 2024 was 67.82%, an increase of 2.10 percentage points year-over-year, while the net margin was 12.52%, a decrease of 3.18 percentage points [2]. Research and Development Pipeline - The company has a robust pipeline with 85 projects in generic drug formulations and 4 projects in medical devices. It has submitted 44 applications for drug approvals, with 12 already approved, and expects to gain 10-20 new approvals by the end of 2024 [2].

北京福元医药股份有限公司 2024年度"提质增效重回报"行动方案的半年度评估报 告 为维护广大投资者利益，提振市场信心，同时完善公司长效激励机制，更紧密、有 效地将股东利益、公司利益和员工利益结合在一起，促进公司健康可持续发展，公司于 2024 年 2 月 6 日发布了股份回购方案，合计拟使用不低于人民币 1 亿元（含）且不超过 人民币 2 亿元（含）的自有资金以集中竞价交易方式回购公司部分（A 股）股份，用于 未来股权激励或员工持股计划。截至 2024 年 9 月 30 日，公司通过集中竞价交易方式已 累计回购股份 12,000,000 股，已回购股份占公司总股本的比例约为 2.50%，成交的最高 价为 15.59 元/股，最低价为 13.59 元/股，已支付的总金额为 176,169,816.92 元（不 含交易费用）。 三、重视股东回报，增强股东获得感 公司高度重视对投资者的合理投资回报，遵照相关法律法规等要求严格执行股东分 红回报规划及利润分配政策，积极回报投资者。公司 2023 年度利润分配方案为：以实 施权益分派股权登记日登记的总股本扣减公司回购专用证券账户中股份为基数，向全体 股东每股派发现金红 ...

证券代码：601089 证券简称：福元医药 公告编号：临2024-072 北京福元医药股份有限公司 第二届董事会第十五次会议决议公告 具体内容详见公司披露于上海证券交易所网站的《北京福元医药股份有限公司 2024 年第三季度报告》。本议案已经董事会审计委员会审议通过，并同意提交董事会审议。 表决情况：同意 9 票，反对 0 票，弃权 0 票。 （二）审议通过《关于 2024 年度"提质增效重回报"行动方案的半年度评估报 告的议案》 具体内容详见公司披露于上海证券交易所网站的《北京福元医药股份有限公司 2024 年度"提质增效重回报"行动方案的半年度评估报告》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 北京福元医药股份有限公司（以下简称"公司"）第二届董事会第十五次会议于 2024 年 1 0 月 1 8 日以书面及邮件等方式发出会议通知，并于 2024 年 1 0 月 23 日 在北京以现场结合通讯表决的方式召开会议。会议应参加表决的董事 9 名，实际参加 表决的董事 9 名。会议由董事长黄河先 ...

Revenue and Profit Performance - Revenue for the third quarter was RMB 891.53 million, a 7.02% increase compared to the same period last year[2] - Total operating revenue for the first three quarters of 2024 reached RMB 2,547,022,297.14, an increase from RMB 2,462,880,582.11 in the same period of 2023[15] - Net profit attributable to shareholders was RMB 110.33 million, a decrease of 14.74% year-over-year[2] - Net profit for the first three quarters of 2024 was RMB 404,081,251.12, up from RMB 383,031,171.23 in 2023[17] - Net profit attributable to parent company shareholders reached RMB 400,949,905.30, an increase of 5.6% compared to the same period last year[18] - Comprehensive income totaled RMB 404,081,251.12, up 5.5% year-over-year[18] Earnings Per Share (EPS) and Return on Equity (ROE) - Basic earnings per share (EPS) for the quarter was RMB 0.24, a decrease of 11.11% year-over-year[4] - Basic earnings per share (EPS) increased to RMB 0.85, up 7.6% from RMB 0.79 in the previous year[18] - Weighted average return on equity (ROE) for the quarter was 2.97%, a decrease of 0.95 percentage points year-over-year[4] Cash Flow and Financial Position - Operating cash flow for the first three quarters reached RMB 490.00 million, up 18.33% compared to the same period last year[2] - Cash flow from operating activities grew by 18.3% to RMB 490,004,394.07[19] - The company's monetary funds as of September 30, 2024, were 974,094,073.63 yuan, a decrease from 2,530,809,346.00 yuan at the end of 2023[12] - Cash and cash equivalents at the end of the period decreased by 60.6% to RMB 973,786,073.63[20] - Investment activities resulted in a net cash outflow of RMB 1,568,523,571.52, primarily due to significant cash payments related to other investment activities[20] - The company received RMB 1,145,998,981.92 from other investment-related activities, a significant increase compared to RMB 385,000,000.00 in the previous year[19] Assets and Liabilities - Total assets at the end of the reporting period were RMB 4.54 billion, a slight decrease of 0.24% compared to the end of the previous year[4] - Total assets as of Q3 2024 were RMB 4,536,654,003.08, slightly down from RMB 4,547,790,301.79 at the end of 2023[13] - Total liabilities as of Q3 2024 were RMB 1,068,549,101.43, a slight decrease from RMB 1,071,251,195.74 at the end of 2023[14] - Shareholders' equity as of Q3 2024 was RMB 3,468,104,901.65, compared to RMB 3,476,539,106.05 at the end of 2023[14] - Total non-current assets as of Q3 2024 were RMB 1,418,101,246.71, up from RMB 1,219,049,736.98 at the end of 2023[13] Operating Costs and Expenses - Operating costs for the first three quarters of 2024 were RMB 2,143,616,163.40, up from RMB 2,036,414,629.57 in 2023[17] - R&D expenses increased to RMB 297,591,745.37 in the first three quarters of 2024, compared to RMB 221,065,440.83 in 2023[17] - Sales expenses for the first three quarters of 2024 were RMB 917,476,764.29, slightly up from RMB 914,910,003.25 in 2023[17] - Interest income for the first three quarters of 2024 was RMB 32,122,065.94, down from RMB 43,179,389.79 in 2023[17] Non-Recurring Gains and Losses - Government subsidies received during the period amounted to RMB 2.25 million, contributing to non-recurring gains[5] - Bank financial product income contributed RMB 4.71 million to non-recurring gains[5] - Non-recurring gains and losses totaled RMB 4.84 million for the quarter[6] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 24,107[8] - New Hope Group holds 176,316,354 shares, accounting for 36.73% of the total shares[8] - Xinchang Qinjin Investment Co., Ltd. holds 98,337,233 shares, accounting for 20.49% of the total shares[8] - Beijing Huakang Taifeng Technology Co., Ltd. holds 70,240,881 shares, accounting for 14.63% of the total shares[8] - Hong Kong Securities Clearing Company holds 9,446,923 shares, accounting for 1.97% of the total shares[8] - The company repurchased 12,000,000 shares, accounting for 2.50% of the total shares, with a total payment of 176,169,816.92 yuan[10] Sales and Inventory - Sales revenue from goods and services reached RMB 2,516,657,281.73, a 6.8% increase year-over-year[19] - The company's accounts receivable as of September 30, 2024, were 347,584,668.10 yuan, slightly increased from 346,134,907.22 yuan at the end of 2023[12] - The company's inventory as of September 30, 2024, was 344,014,911.90 yuan, increased from 307,419,355.37 yuan at the end of 2023[12] Trading Financial Assets - The company's trading financial assets as of September 30, 2024, were 1,328,000,000.00 yuan[12]

证券代码：601089 证券简称：福元医药 公告编号：临 2024-071 北京福元医药股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 说明会类型 会议召开时间：2024 年 10 月 30 日(星期三) 上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（网址： 本次投资者说明会以网络互动形式召开，公司将针对 2024 年第 三季度的经营成果及财务指标的具体情况与投资者进行互动交流和 沟通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 10 月 30 日 上午 10:00-11:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 10 月 23 日(星期三) 至 10 月 29 日(星期 二) ...

证券代码：601089 证券简称：福元医药 公告编号：临 2024-070 北京福元医药股份有限公司 一、 回购股份的基本情况 北京福元医药股份有限公司(以下简称"公司"）于 2024 年 2 月 5 日召开第二 届董事会第九次会议，会议审议通过了《关于<公司以集中竞价交易方式回购股份 的预案>的议案》，同意公司使用自有资金以集中竞价交易方式回购公司股份用于 后续实施股权激励或员工持股计划，回购价格不超过人民币 24.10 元/股（含）， 回购资金总额不低于人民币 1 亿元且不超过人民币 2 亿元，回购期限为自董事会 审议通过回购股份方案之日起 12 个月内。具体内容详见公司在上海证券交易所网 站（www.sse.com.cn）披露的相关公告（公告编号：临 2024-003、临 2024-005）。 因公司实施 2023 年度利润分配，回购股份价格上限由不超过人民币 24.10 元 /股（含）调整为不超过人民币 23.61 元/股（含），具体内容详见公司在上海证券 交易所网站（www.sse.com.cn）于 2024 年 6 月 20 日披露的《北京福元医药股份 有限公司关于 2023 年年度权益分派实施后 ...

北京福元医药股份有限公司投资者关系活 动记录表 编号：2024-19 | --- | --- | --- | |------------------|---------------------------|--------------------------------------------------------| | | √特定对象调研 £分析师会议 | | | 投资者关系活动类 | □媒体采访 £业绩说明会 | | | 别 | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ | 其他（请文字说明其他活动内容） | | 参与单位名称及人 | 太平洋医药 周豫 刘哲涵 | | | 员姓名 | | 相聚资本 邓巧 中邮自营 鲁春娥 | | | 仁桥资产 谢沛林 | | | 时间 | 15：00-15 ： 30 | | | 地点 | 电话会议 | | | 上市公司接待人员 | 董事会秘书 李永 | | | | 证券事务代表 郑凯微 | | | 姓名 | 董秘助理 姜钰 | | | 投资者关系活动主 | 1. | 上半年利润增速不错，主要是由于哪方面的因素？三季度公 | | 要内容介 ...